Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth Factor β Secretion
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The development of therapeutic strategies for the treatment of cirrhosis has become an important focus for basic and clinical researchers. Adrenergic receptor antagonists have been evaluated as antifibrotic drugs in rodent models of carbon tetrachloride (CCl4)-induced cirrhosis. The aim of the present study was to evaluate the effects of carvedilol and doxazosin on fibrosis/cirrhosis in a hamster animal model. Methods: Cirrhotic-induced hamsters were treated by daily administration of carvedilol and doxazosin for 6 weeks. Hepatic function and histological evaluation were conducted by measuring biochemical markers, including total bilirubin, aspartate aminotransferase, alanine aminotransferase and albumin, and liver tissue slices. Additionally, transforming growth factor β (TGF-β) immunohistochemistry was analyzed. Results: Biochemical markers revealed that hepatic function was restored after treatment with doxazosin and carvedilol. Histological evaluation showed a decrease in collagen type I deposits and TGF-β-secreting cells. Conclusions: Taken together, these results suggest that the decrease in collagen type I following treatment with doxazosin or carvedilol is achieved by decreasing the profibrotic activities of TGF-β via the blockage of α1- and β-adrenergic receptor. Consequently, a diminution of fibrotic tissue in the CCl4-induced model of cirrhosis is achieved.
Abstract
Background/Aims: The development of therapeutic strategies for the treatment of cirrhosis has become an important focus for basic and clinical researchers. Adrenergic receptor antagonists have been evaluated as antifibrotic drugs in rodent models of carbon tetrachloride (CCl4)-induced cirrhosis. The aim of the present study was to evaluate the effects of carvedilol and doxazosin on fibrosis/cirrhosis in a hamster animal model. Methods: Cirrhotic-induced hamsters were treated by daily administration of carvedilol and doxazosin for 6 weeks. Hepatic function and histological evaluation were conducted by measuring biochemical markers, including total bilirubin, aspartate aminotransferase, alanine aminotransferase and albumin, and liver tissue slices. Additionally, transforming growth factor β (TGF-β) immunohistochemistry was analyzed. Results: Biochemical markers revealed that hepatic function was restored after treatment with doxazosin and carvedilol. Histological evaluation showed a decrease in collagen type I deposits and TGF-β-secreting cells. Conclusions: Taken together, these results suggest that the decrease in collagen type I following treatment with doxazosin or carvedilol is achieved by decreasing the profibrotic activities of TGF-β via the blockage of α1- and β-adrenergic receptor. Consequently, a diminution of fibrotic tissue in the CCl4-induced model of cirrhosis is achieved.
참고문헌 (27)
- Ueha S, "Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis", Front Immunol, 3, pp.71~ (2012)
- Firpi RJ, "The natural history of hepatitis C cirrhosis after liver transplantation", Liver Transpl, 15, pp.1063~1071 (2009)
- Aghemo A, "Cirrhosis regression in chronic hepatitis C: an old tale with a new ending", Gastroenterology, 136, pp.1447~1449 (2009)
- Wynn TA, "Cellular and molecular mechanisms of fibrosis", J Pathol, 214, pp.199~210 (2008)
- Holt AP, "Immune interactions in hepatic fibrosis", Clin Liver Dis, 12, pp.861~882 (2008)
- Genescà J, "Cytokines and liver cirrhosis", Med Clin, 122, pp.457~458 (2004)
- Hellerbrand C, "Molecular targets for antifibrotic therapy in liver disease: using magic bullets for crossfire rather than a one-sided shotgun attack", Gut, 63, pp.1039~1041 (2014)
- Sancho-Bru P, "Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells", Am J Physiol Gastrointest Liver Physiol, 291, pp.G877~G884 (2006)
- Oben JA, "Hepatic fibrogenesis requires sympathetic neurotransmitters", Gut, 53, pp.438~445 (2004)
- Oben JA, "Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury", Hepatology, 38, pp.664~673 (2003)
- Dubuisson L, "Inhibition of rat liver fibrogenesis through noradrenergic antagonism", Hepatology, 35, pp.325~331 (2002)
- Tripathi D, "The role of carvedilol in the management of portal hypertension", Eur J Gastroenterol Hepatol, 22, pp.905~911 (2010)
- Dandona P, "Antioxidant activity of carvedilol in cardiovascular disease", J Hypertens, 25, pp.731~741 (2007)
- Hamdy N, "New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage", Toxicol Appl Pharmacol, 261, pp.292~299 (2012)
- Lepor H, "The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia", Rev Urol, 8(4), pp.S3~S9 (2006)
- Gressner AM, "Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets", J Cell Mol Med, 10, pp.76~99 (2006)
- Junqueira LC, "Differential staining of collagens type I, II and III by Sirius Red and polarization microscopy", Arch Histol Jpn, 41, pp.267~274 (1978)
- Roskams T, "Neuroregulation of the neuroendocrine compartment of the liver", Anat Rec A Discov Mol Cell Evol Biol, 280, pp.910~923 (2004)
- Motoyama H, "Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver", Lab Invest, 94, pp.192~207 (2014)
- Komeda K, "Chymase inhibition attenuates tetrachloride-induced liver fibrosis in hamsters", Hepatol Res, 40, pp.832~840 (2010)
- Popper H, "Pathologic aspects of cirrhosis: a review", Am J Pathol, 87, pp.228~264 (1977)
- Santra A, "Development of an animal model of hepatic fibrosis by excretory-secretory antigen of Ascaris suum", Indian J Gastroenterol, 19, pp.119~121 (2000)
- Gallego-Delgado J, "Long-term organ protection by doxazosin and", or quinapril as antihypertensive therapy, 2006, pp.19, 588~598
- Perlini S, "Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy", Hypertension, 46, pp.1213~1218 (2005)
- Pawluczyk IZ, "The role of the alpha-1 adrenoceptor in modulating human mesangial cell matrix production", Nephrol Dial Transplant, 21, pp.2417~2424 (2006)
- Shi MN, "Relationship between transforming growth factor beta1 and anti-fibrotic effect of interleukin-10", World J Gastroenterol, 12, pp.2357~2362 (2006)
- Aldaba-Muruato LR, "Allopurinol reverses liver damage induced by chronic carbon tetrachloride treatment by decreasing oxidative stress, TGF-beta production and NF-kappaB nuclear translocation", Pharmacology, 92, pp.138~149 (2013)